Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -337.86% is 72% above its 3-year average of -1205.84%, near the high end of its 3-year range (-26142.37%–-259.98%).
0.46% above its 12-month average of -339.42%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2027 (2026-06-30): -328.90%.
EBITDA MARGIN
-337.86%
EBITDA MARGIN AVG TTM
-339.42%
EBITDA MARGIN AVG 3Y
-1205.84%
EBITDA MARGIN AVG 5Y
-1205.84%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.46%
CURRENT VS 3Y AVG
+71.98%
CURRENT VS 5Y AVG
+71.98%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Beyond Air, Inc.
Market Cap
$1.84M
EBITDA Margin
-337.86%
TTM Avg
-339.42%
3Y Avg
-1205.84%
5Y Avg
-1205.84%
Market Cap
$1.84M
EBITDA Margin
-310.90%
TTM Avg
-355.50%
3Y Avg
-975.40%
5Y Avg
-1515.38%
Market Cap
$1.81M
EBITDA Margin
-84360.00%
TTM Avg
-66230.00%
3Y Avg
-193151.74%
5Y Avg
-158287.83%
Market Cap
$1.64M
EBITDA Margin
-5921.09%
TTM Avg
-6219.48%
3Y Avg
-5704.41%
5Y Avg
-5333.72%
Market Cap
$2.13M
EBITDA Margin
-866.57%
TTM Avg
-750.00%
3Y Avg
-6212.81%
5Y Avg
-4728.90%
Market Cap
$2.14M
EBITDA Margin
-106.55%
TTM Avg
-88.50%
3Y Avg
-112.46%
5Y Avg
-107.91%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Beyond Air, Inc. (XAIR) | $1.84M | -337.86% | -339.42% | -1205.84% | -1205.84% |
| Tenon Medical, Inc. (TNON)vs › | $1.84M | -310.90% | -355.50% | -975.40% | -1515.38% |
| Profusa, Inc. Common Stock (PFSA)vs › | $1.83M | N/A | N/A | N/A | N/A |
| Alaunos Therapeutics, Inc. (TCRT)vs › | $1.81M | -84360.00% | -66230.00% | -193151.74% | -158287.83% |
| TransCode Therapeutics, Inc. (RNAZ)vs › | $1.88M | N/A | N/A | N/A | N/A |
| Autonomix Medical, Inc. (AMIX)vs › | $1.88M | N/A | N/A | N/A | N/A |
| Silo Pharma, Inc. (SILO)vs › | $1.64M | -5921.09% | -6219.48% | -5704.41% | -5333.72% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.13M | -866.57% | -750.00% | -6212.81% | -4728.90% |
| Vivos Therapeutics, Inc. (VVOS)vs › | $2.14M | -106.55% | -88.50% | -112.46% | -107.91% |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.52M | N/A | N/A | N/A | N/A |
Gross Margin
4.2%
EBITDA Margin
-337.9%
Operating Margin
-378.2%
Net Margin
-435.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -328.90% |
| 2026-03-31 | -351.76% |
| 2025-12-31 | -259.98% |
| 2025-09-30 | -376.29% |
| 2025-06-30 | -380.17% |
| 2025-03-31 | -541.23% |
| 2024-12-31 | -941.79% |
| 2024-09-30 | -1489.60% |
| 2024-06-30 | -1866.76% |
| 2024-03-31 | -2531.28% |
| 2023-12-31 | -4196.42% |
| 2023-09-30 | -7124.27% |
| 2023-06-30 | -26142.37% |
| 2021-03-31 | -3433.10% |
| 2020-12-31 | -3727.52% |
| 2020-09-30 | -1394.62% |
| 2020-06-30 | -2859.78% |
| 2020-03-31 | 2648.36% |
| 2019-12-31 | -1506.41% |
| 2019-09-30 | -654.95% |
| 2019-06-30 | -604.31% |
| 2019-03-31 | 45.73% |
